Author pages are created from data sourced from our academic publisher partnerships and public sources.
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Management of Helicobacter pylori infection is evolving and in this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010. In… Expand
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. pylori… Expand
European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.
European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease
Aliment Pharmacol Ther 2011; 34: 125–145
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
BACKGROUND & AIMS Helicobacter pylori infection is increasingly difficult to treat. The purpose of these consensus statements is to provide a review of the literature and specific, updated… Expand
Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review
The urea breath test is a non‐invasive, simple and safe test which provides excellent accuracy both for the initial diagnosis of Helicobacter pylori infection and for the confirmation of its… Expand
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
OBJECTIVES:To review the frequency with which infliximabloses its effect and dose “intensification” is required for Crohn's disease treatment.METHODS:Bibliographical searches were performed in… Expand
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
Faecal calprotectin has been proposed as a non-invasive surrogate marker of intestinal inflammation in inflammatory bowel disease. Close correlation between faecal calprotectin concentration and… Expand
Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients
Background:To evaluate the safety of thiopurines in patients with inflammatory bowel disease. To identify predictive factors associated with the development of thiopurine-induced adverse events.… Expand
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
Background: The purpose of the study was to determine the role of fecal calprotectin and lactoferrin in the prediction of inflammatory bowel disease relapses, both in patients with ulcerative colitis… Expand